HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia

CompletedOBSERVATIONAL
Enrollment

774

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

March 29, 2024

Study Completion Date

March 29, 2024

Conditions
Breast Cancer
Trial Locations (29)

Unknown

Research Site, Arkhangelsk

Research Site, Barnaul

Research Site, Belgorod

Research Site, Chelyabinsk

Research Site, Grozny

Research Site, Irkutsk

Research Site, Kaluga

Research Site, Kchabarovsk

Research Site, Khanty-Mansiysk

Research Site, Kommunarka

Research Site, Kostroma

Research Site, Krasnodar

Research Site, Krasnoyarsk

Research Site, Moscow

Research Site, Perm

Research Site, Pyatigorsk

Research Site, Ryazan

Research Site, Saint Petersburg

Research Site, Sakhalin

Research Site, Saransk

Research Site, Sochi

Research Site, Surgut

Research Site, Tomsk

Research Site, Tver'

Research Site, Ufa

Research Site, Ulan-Ude

Research Site, Vladivostok

Research Site, Volgograd

Research Site, Yaroslavl

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY